Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.78B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.89M
Average 0.82M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$84.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -31.8% | +219.0% (5yr)12 analysts |
| Net Income | N/A | N/A | N/A | N/A12 analysts |
| EBIT | N/A | N/A | N/A | N/A12 analysts |
Analysis
Recent growth has been strongest in Revenue at -31.8% over three years. Forward estimates point to Revenue at +219.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Immunovant, Inc. NASDAQ:IMVT | $7.07B | $34.18 | Not rated | -14.3 | +42.69% |
Vera Therapeutics, Inc. NASDAQ:VERA | $2.03B | $28.10 | Not rated | -6.8 | -4.02% |
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | $46.25 | Overvalued | -59.7 | +88.77% |
MoonLake Immunotherapeutics NASDAQ:MLTX | $1.06B | $12.50 | Not rated | -5.4 | -15.15% |
Alumis Inc. Common Stock NASDAQ:ALMS | $724.84M | $5.60 | Not rated | -12.2 | -37.43% |
Q32 Bio Inc. NASDAQ:QTTB | $260.64M | $8.71 | Not rated | 5.4 | +339.38% |
Artiva Biotherapeutics, Inc. NASDAQ:ARTV | $198.22M | $4.01 | Not rated | -2.7 | +20.82% |
Cartesian Therapeutics, Inc. NASDAQ:RNAC | $193.69M | $6.35 | Not rated | -1.7 | -17.62% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $42.65M | $0.68 | Not rated | -4.0 | -74.53% |
Continue the stock analysis
Jump to another research area for this company.